Cotempla is an extended-release orally disintegrating tablet intended to treat ADHD in patients ages 6 to 17 years. The pill dissolves in a patient’s mouth with no need for water or chewing, according to a news release.
Neos plans to launch Cotempla as a portable blister pack this fall.
More articles on supply chain:
25 top supply chains in 2017, as ranked by Gartner
Baltimore’s naloxone supply dwindling as opioid overdose rates surge
Patients seeking financial assistance for $750k Biogen drug must sign away PHI
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
